Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

NCT03065062 · clinicaltrials.gov ↗

PHASE1

Phase

SUSPENDED

Status

75

Enrollment

OTHER

Sponsor class

Stopped Funding and drug supply to continue the study are pending.

Conditions

Lung Cancer Squamous Cell
Solid Tumors
Head & Neck Cancer
Pancreatic Cancer

Interventions

DRUG: Palbociclib
DRUG: Gedatolisib

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]